Harpoon Therapeutics, Inc. - HARP STOCK NEWS

Harpoon Therapeutics (Nasdaq: HARP) presented preclinical results for its key clinical programs, HPN328 and HPN217, at the AACR Annual Meeting 2023. HPN328, a T cell engager targeting DLL3, demonstrated potential for long-term anti-tumor immunity and enhanced activity when combined with anti-PD-L1 antibodies, indicating promising durability in cancer treatments. HPN217, targeting BCMA, showed increased potency with γ-secretase inhibitors, suggesting effective combination therapies. Both programs are currently in ongoing clinical trials, with HPN217 already receiving Fast Track designation from the FDA for multiple myeloma. These developments underline Harpoon's innovative approach to harnessing the immune system for cancer treatment.

Harpoon Therapeutics has announced promising preclinical data for two new ProTriTAC™ T cell engager candidates targeting TROP2 and integrin-beta6 (ITGB6) in solid tumors. Presented at the AACR Annual Meeting, these candidates aim to improve therapeutic outcomes in cancers where these proteins are overexpressed. Notably, both candidates demonstrated effective anti-tumor activity in rodent models with complete tumor eradication observed at doses as low as 30 µg/kg. ITGB6 ProTriTAC exhibited favorable safety in cynomolgus monkeys, while TROP2 ProTriTAC showed some on-target toxicity at higher doses. The company aims to advance these findings to clinical studies, potentially enhancing treatment options for patients with solid tumors.

Harpoon Therapeutics, a clinical-stage immuno-oncology company, announced its participation in the Canaccord Horizons in Oncology Conference on April 20, 2023. Julie Eastland, President and CEO, and Luke Walker, M.D., Chief Medical Officer, will join a panel discussion titled “T-Cell Engagers Coming of Age”, scheduled from 11:00-11:45 a.m. ET.

Harpoon specializes in developing T cell engagers using its proprietary TriTAC® platform, targeting solid tumors and hematologic malignancies. The company also employs the ProTriTAC™ and extended release TriTAC-XR platforms to enhance treatment efficacy and manage side effects. For more information, visit www.harpoontx.com.

Harpoon Therapeutics (HARP) reported its 2022 financial results, highlighting a cash position of $53.1 million, after completing a $25 million equity financing to fund operations into 2024. The company is on schedule with the enrollment of its clinical trial programs HPN217 and HPN328, seeking to present data updates and recommended Phase 2 doses later this year. For 2022, revenue increased to $31.9 million, driven by collaborations with AbbVie, while R&D expenses rose to $81.4 million. The net loss narrowed to $67.7 million, improving from $116.7 million in 2021. The company plans to present five posters at AACR 2023, underscoring advancements in its clinical pipeline.

Harpoon Therapeutics announced the closing of a private placement of redeemable preferred stock and warrants, raising $25 million in gross proceeds. The funding was backed by both new and existing investors, including New Leaf and OrbiMed. The company plans to utilize the net proceeds for ongoing Phase 1 clinical studies of its TriTAC T cell engagers, specifically HPN217 for multiple myeloma and HPN328 for neuroendocrine tumors. The investment will support operations into the second half of 2024. The private placement consists of 25,000 shares of preferred stock and warrants for 7,485,762 shares of common stock, with a 35% premium on the exercise price.

Harpoon Therapeutics (Nasdaq: HARP) announced five preclinical investigations on its T cell engagers, HPN328 and HPN217, at the AACR Annual Meeting set for April 14-19, 2023, in Orlando, Florida. The presentations support the validation of Harpoon's Tri-specific T cell Activating Construct (TriTAC) platform and the next-generation ProTriTAC technology for targeting solid tumors. Notably, the data reveals effective anti-tumor activity in immunocompetent mouse models. Harpoon anticipates further clinical validation of these findings, bolstering its research efforts and potential therapeutic applications in oncology.